Junevity Inc.

Junevity Inc. was founded in 2023 in San Francisco, US, specializing in therapies targeting aging-related conditions. The founder's specific background is not available, but the strategic foundation of the company highlights an emphasis on innovative therapeutic solutions. Junevity specializes in the development of cell reset therapeutics aimed at combating longevity-related diseases through innovative use of small interfering RNA (siRNA) technology.

Their core product offerings leverage the RESET Platform, which utilizes advanced machine learning and high-throughput screening to identify and restore the expression of transcription factors that regulate cellular health. The primary end use cases targeted by Junevity include Obesity, Type 2 Diabetes, and Frailty, addressing conditions that significantly impact global public health. By focusing on cellular damage at the transcriptional level, Junevity aims to reverse the effects of aging and improve quality of life for affected populations. The company’s products are designed for distribution in major geographical markets, including North America, Europe, and parts of Asia, where the prevalence of these diseases is particularly high.

Junevity operates on a model that incorporates both B2B and direct-to-consumer transactions, aiming to establish partnerships with healthcare providers and research institutions. The revenue structure is primarily based on the sale of their novel siRNA therapeutics, which are expected to be priced competitively within the biotechnology market. These therapeutics are positioned as flagship products within their therapeutic pipeline, addressing critical health challenges associated with aging. The transaction process typically involves direct sales to healthcare institutions and potential subscription models for ongoing therapeutic supplies.

By focusing on long-term partnerships with stakeholders in the healthcare sector, Junevity is well-positioned to generate sustainable revenue through its innovative approach to disease reversal and longevity enhancement. In November 2025, Junevity Inc. raised USD 10 million in seed funding co-led by Godfrey Capital and Goldcrest Capital. The round was part of a larger USD 10 million seed funding round.

The company plans to utilize the November 2025 funding to advance lead candidate JUN_01 for type 2 diabetes and obesity to first-in-human studies through IND-enabling and initial clinical studies.